

# Antoni Sicras-Mainar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6334922/publications.pdf>

Version: 2024-02-01

18  
papers

199  
citations

1162367

8  
h-index

1125271

13  
g-index

20  
all docs

20  
docs citations

20  
times ranked

231  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology and costs of depressive disorder in Spain: the EPICO study. <i>European Neuropsychopharmacology</i> , 2021, 50, 93-103.	0.3	28
2	Economic impact of treatment-resistant depression: A retrospective observational study. <i>Journal of Affective Disorders</i> , 2021, 295, 578-586.	2.0	24
3	Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2022, 75, 31-38.	0.4	20
4	The Effect of Quitting Smoking on Costs and Healthcare Utilization in Patients with Chronic Obstructive Pulmonary Disease: A Comparison of Current Smokers Versus Ex-Smokers in Routine Clinical Practice. <i>Lung</i> , 2014, 192, 505-518.	1.4	16
5	Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2019, Volume 14, 2121-2129.	0.9	14
6	Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2094200.	1.2	14
7	Disease Burden and Costs in Moderate-to-Severe Chronic Osteoarthritis Pain Refractory to Standard of Care: Ancillary Analysis of the OPIOIDS Real-World Study. <i>Rheumatology and Therapy</i> , 2021, 8, 303-326.	1.1	9
8	Influence of the CYP2D6 Isoenzyme in Patients Treated with Venlafaxine for Major Depressive Disorder: Clinical and Economic Consequences. <i>PLoS ONE</i> , 2014, 9, e90453.	1.1	9
9	Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care. <i>Annals of General Psychiatry</i> , 2012, 11, 22.	1.2	8
10	Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en España. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 465-475.	0.2	8
11	Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096465.	0.4	5
12	Clinical and Economic Consequences of Inhaled Corticosteroid Doses and Particle Size in Triple Inhalation Therapy for COPD: Real-Life Study. <i>International Journal of COPD</i> , 2020, Volume 15, 3291-3302.	0.9	4
13	Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110105.	1.2	4
14	Uso concomitante de antivirales de acción directa (AAD) y fármacos con acción sobre el sistema nervioso central: Consideraciones en el perfil actual del paciente con hepatitis C. <i>Revista De Psicología De La Salud</i> , 2020, 0, 1551.	0.2	3
15	All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 853-867.	0.7	3
16	Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study. <i>Open Access Rheumatology: Research and Reviews</i> , 2022, Volume 14, 25-38.	0.8	2
17	Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e053964.	0.8	2
18	Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study. <i>Clinical Drug Investigation</i> , 2021, 41, 1055-1066.	1.1	0